Oncology Nurse Advisor5d
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Hosted on MSN1mon
Woman Shares Early Signs of One-in-a-million Tumour That 'Ate Her Bones'; Know All About Osteoclastoma
After months of being dodged, Ashley was diagnosed with Giant Cell Tumour, a one-in-a-million, noncancerous tumor that develops ... Related News | Why Are Skin Cancer Cases Increasing In India?
Medscape3d
FDA Approves Fourth Denosumab Biosimilar
Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors Treatment of adults and skeletally mature adolescents with giant cell ...
Yahoo Finance26d
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...
Business Wire1mon
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor ...